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StrokeAbstract Atrial ﬁbrillation (AF) is the most common sustained arrhythmia encountered in clinical
practices with signiﬁcant morbidity, mortality and socioeconomic burden. Its prevalence and inci-
dence are on the rise due to an increase in population age. AF has complex electrophysiological
mechanisms, etiology and natural history and thus management is a challenge. More than 80%
of cases in AF are related to an underlying structural heart disease. Stroke and congestive heart fail-
ure remain the most signiﬁcant complications of AF. Depending on the patient’s symptoms, dura-
tion and type of AF, structural heart disease and non-cardiac comorbidities, several management
options are currently available. Asymptomatic AF carries similar risks as symptomatic AF. Rate
control approach in majority of cases especially elderly patients is reasonable. Novel anticoagula-
tion agents have shifted the paradigm in stroke prevention and management in patients with AF.
Catheter ablation of paroxysmal AF in patients with no to minimal structural heart disease who
have failed at least one antiarrhythmic agent appears reasonable.
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Atrial ﬁbrillation (AF) is the most common sustained arrhyth-
mia worldwide with a current prevalence of 2.7–6.1 million inthe United States and Europe with an estimated increase of
15.9 million in 2050.1 We ﬁrst discuss selected topics on
etiologies followed by current management options and future
directions.
Figure 1 Different types of AF according to its duration. ( CV:
Cardioversion) Camm J, Kirchhof P, Lip GYH, et al. Guidelines
for management of atrial ﬁbrillation. Eur Heart J 2010;31:2369–
2429.
Update on atrial ﬁbrillation 1952. Clinical presentation of atrial ﬁbrillation
AF is generally diagnosed by an electrocardiogram and is
characterized by absence of P-wave, with ﬁbrillatory waves
usually <200 ms with absolutely irregularly irregular heart
rate. Symptoms of AF depend mainly on the rate, irregular-
ity, and underlying structural heart disease, such as heart
failure (HF) and coronary artery disease (CAD) and valvu-Figure 2 (A–D) Panel A: AF with rapid ventricular response. Pan
AVNRT with conversion to sinus rhythm and reinitiation of AF in plar heart disease. AF may present as rapid palpitations,
chest pain, and shortness of breath, dizziness, light-headed-
ness and rarely syncope where rapid ventricular response is
present. Diminished exercise capacity (malaise and fatigue)
and symptoms of transient ischemic attack and stroke are
among other symptoms. AF impacts exercise capacity in
patients with HF either with preserved or reduced systolic
function.2
On the other hand many episodes of AF remain unnoticed
‘‘silent’’ and are often detected during routine physical exami-
nation or upon admissions to the hospital for other causes
such as HF and stroke.
3. Classiﬁcation of atrial ﬁbrillation
AF is classiﬁed into four categories based on its duration as
shown in Fig. 1 below.
(1) First detected or diagnosed AF independent of its dura-
tion, and presence or absence of any symptoms.
(2) Paroxysmal AF: Episodes lasting less than 24–48 h that
terminate spontaneously but may also last up to
7 days. After this period the rate of spontaneous termi-
nation is low and anticoagulation is warranted. Epi-
sodes that are longer than 30 seconds are considered
as recurrences. This duration is considered in trials
for drug efﬁcacy.
(3) Persistent AF: Episodes lasting longer than 7 days that
require termination by either direct electrical cardiover-
sion or pharmacological intervention.el B: Atrial ﬂutter with 2:1 AV conduction. Panel C: Sustained
anel D.
Table 1 Risk factors and markers for AF. Modiﬁed from Shenasa et al. Atrial ﬁbrillation in different clinical substrates. In Shenasa M,
Camm JA, editors. Management of atrial ﬁbrillation: a practical approach. Oxford University Press, in publication.
Traditional risk factors Novel risk factors Markers
Age, male sex Reduced vascular compliance Increased arterial stiﬀness
Hypertension/diabetes mellitus Atherosclerosis Prolonged QRS duration
Alcohol consumption Insulin resistance P-wave dispersion
Clinical conditions Environmental factors (air pollution, etc.) Low birth weight
Left ventricular hypertrophy Excess vitamin D Inﬂammatory markers
Myocardial infarction/heart failure Atrial ﬁbrosis Neurohormones
Valvular heart disease Antiarrhythmic agents Genetic variants
Thyroid disease Extreme exercise Pulse pressure
Prior cardiac surgery/post-cardiac surgery Inﬂammation Thyroid stimulation hormone, T3, T4
Congenital heart disease Obstructive sleep apnea ANP
Cardiomyopathies Obesity/metabolic syndrome Hs-CRP
Inherited channelopathies Smoking Interleukin-6
Autonomic imbalance Chronic kidney disease Angiotensin II
Markers for ﬁbrosis
Electrolyte imbalance Echocardiographic predictors of AF: - LV fractional
shortening- Mitral annular calciﬁcation- Left atrial
enlargment- LVH ( LV wall thickness)
Pulmonary disease
Figure 3 Illustrates the different etiologies of AF. Many of them maybe interconnected. Modiﬁed from Shenasa et al. Individualized
therapy in patients with atrial ﬁbrillation: new look at atrial ﬁbrillation, Europace 2012.
196 M. Shenasa et al.(4) Long-lasting persistent AF: Episodes lasting longer than
one year. This deﬁnition is created for cases where a
rhythm control strategy is recommended mostly to con-
sider catheter ablation of AF.
(5) Permanent AF: Episodes when patients and their physi-
cian accept to maintain AF, or when restoring sinus
rhythm is not attempted or failed and rate control is
the chosen strategy over rhythm control.
(6) Lone AF: Deﬁned as AF in patients below age 60 with
no clinically detectable structural cardiovascular disease,
which could be paroxysmal, persistent, or permanent.
(7) AF Burden: Deﬁned as the proportion of time patients
are in AF.AF maybe associated with other arrhythmias, the most
common ones being atrial ﬂutter, atrial tachycardia. Less fre-
quently AV nodal reentrant tachycardia (AVNRT) and acces-
sory pathway tachycardia are associated with AF. These
arrhythmias may coexist with AF as seen in Fig. 2A–D (same
patient).
Furthermore, ventricular tachycardia and AF may be seen
in the same patients especially those with advanced HF.
3.1. Atrial ﬁbrillation and quality of life
It is shown that patients with AF have poorer quality of life
compared to healthy individuals.3
Figure 5 Illustrates the interplay of different pathophysiological processes in AF. (MI : myocardial infarction, LV: left ventricular, AF:
atrial ﬁbrillation) Courtesy of Ali Sovari MD.
action potential duration
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contractile
electricalAPD
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structural
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LA pressure a V 
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conduction
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Remodeling in Atrial Fibrillation
Courtesy of Kääb S,
Figure 4 Interplay between the electrical, mechanical and structural remodeling pathways in AF. Courtesy of Stephan Kaab.
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The lifetime risk of developing AF after age 40 is one in four and
will increase with advanced age.1 Essentially, AF is an age-
developed disease, occurring in 10% of patients at the age of
90. AF is more common in Caucasians thanAfrican–Americans
and Hispanics.4 Subclinical silent or asymptomatic AF has
become more recognizable and recent observations suggest it
carries the same risk of stroke as symptomatic AF. AF is one
of the most common arrhythmias for emergency room visits
and hospitalizations and accounts for most of AF related costs.Health outcomes: Incident of AF increases the risk of all
causes as well as cardiovascular mortality by 1.5–2 fold and
the risk is even higher in women (5-fold).1 AF has a diverse eti-
ology as shown in Fig. 3.3.3. Etiologies of atrial ﬁbrillation
AF has a very diverse and often multiple etiologies, such as
hypertension, coronary disease, HF, thyrotoxicosis, acute
myocardial infarction as shown in Fig. 3. Some recently rec-
ognized etiologies and risk factors such as obesity; obstruc-
Figure 6 Relationship between magnitude of atrial ﬁbrosis and types of AF as detected by delayed-enhanced MRI. Courtesy of Nassir
Marrouche. (MRI: Magnetic resonance imaging, AF: Atrial ﬁbrilation)
A
B
Figure 7 Panel A: Demonstrates the interplay between AF and
HF cycle and Panel B HF–AF cycle. (AF, atrial ﬁbrillation; ANP,
198 M. Shenasa et al.tive sleep apnea and impaired renal function are also related
to AF.
Hypertension is the most common cause of AF is followed
by HF, valvular heart disease, left ventricular hypertrophy
(LVH), left atrial enlargement, CAD and diabetes. Less com-
mon etiologies are hyperthyroid state and alcohol use.
Recently, novel etiologies such as obesity, obstructive sleep
apnea (OSA), impaired renal function and smoking have
emerged. A variety of traditional and novel risk factors and
markers are shown below in Table 1.
3.4. Pathophysiology and mechanisms of atrial ﬁbrillation
Since the initial description by Gordon Moe.5 that multiple
reentrant wavelets are present during computer simulations
and experimental models of AF, multiple mechanisms some
of which maybe present simultaneously have been proposed
and can be classiﬁed as follows:6
(A) Single source:
a. Automatic focus from either pulmonary veins (PVs)
or atrial tissues.
b. Mother wave.
c. Fixed rotor.
d. Moving rotor.
(B) Multiple sources:atrial natriuretic peptide; BNP, brain natriuretic peptide; EDP,
end diastolic pressure; LAP, left atrial pressure; HF, heart failure;
LVD, left ventricular dilation). Courtesy of Alfred Bove.1) Multiple foci.
2) Unstable circuits.
3) Multiple wavelengths.
4) Focus + multiple wave lengths.
It is now well established that AF begets AF and cellularand ionic remodeling (electrical, mechanical and neuro hor-
monal) plays a signiﬁcant role in initiation and progression
of AF (Fig. 4).
With the landmark report by Haisseguerre et al.7 rapid
depolarization from PVs that can initiate and perpetrate AFhas led investigators to better understand mechanism(s) of
AF and develop novel therapeutic approaches to AF. The
mechanism by which PV ﬁres and triggers AF is poorly under-
stood, but it may be related to genetic factors, stretch, neuro-
Table 2 Risk scheme for CHADS2 and CHADS2-VASc.
CHADS2
C Congestive HF 1 point
H Hypertension 1 point
A Age P75 yrs 1 point
D Diabetes 1 point
S2 Stroke 2 points
CHADS2-VASc
C Congestive HF 1 point
H Hypertension 1 point
A Age P75 yrs 2 points
D Diabetes 1 point
S2 Stroke 2 points
V Vascular disease 1 points
A Age P65 yrs 1 points
Sc Sex category, female 1 points
Update on atrial ﬁbrillation 199hormonal and autonomic inﬂuences. Non-pulmonary thoracic
veins such as coronary sinus, superior and inferior vena cava
and vein of Marshall can but less often, be a source of
abnormal ﬁring and triggers of AF. Autonomic innervation
to the heart particularly in the atria as well as intrinsic
neural pelxi in the atria, as well as direct sympathetic and para-
sympathetic activity can play a signiﬁcant role in the pathogen-
esis of AF.
3.5. Diagnosis and detection of atrial ﬁbrillation
First step in diagnosis of AF is by rhythm documentation,
either by electrocardiogram (ECG), rhythm strips or long-term
electrocardiography, such as Holter monitor or event record-
ers. Recently, many episodes of AF asymptomatic so-called
‘‘silent’’ have been documented by interrogation of implant-
able pacemakers, implantable cardioverter deﬁbrillators or
loop recorders. Importantly the stroke risk of asymptomatic
AF remains the same or even higher than symptomatic ones
(see section on Stroke and AF).8 The varieties of AF monitor-
ing and detection devices that are currently available include
event recorders, smart phones, etc.
3.6. Inﬂammation, ﬁbrosis and atrial ﬁbrillation
Several studies have elaborated on the role of inﬂammation
and subsequently ﬁbrosis as an integral part of the
pathophysiology of AF.9 A complex cascade of inﬂammatory
processes and oxidative stress leading to ﬁbrosis and subse-
quently AF is depicted in Fig. 5.6
Brieﬂy, AF is clearly associated with increased levels of
inﬂammatory markers and atrial biopsies in patients with
AF have also conﬁrmed the presence of inﬂammation. There
is evidence supporting a link between inﬂammation and AF,
and some of the drug therapies, such as the angiotensin-con-
verting-enzyme (ACE) inhibitors, angiotensin receptor block-
ers (ARBs), steroids, ﬁsh oils, and vitamin C, that might be
efﬁcacious in the prevention of AF by modulating inﬂamma-
tory pathways. However, randomized trial and longitudinal
studies are needed to conﬁrm the direct relationship between
AF and inﬂammation.Figure 8 Example of atrial tachycardia from interrogation of an
asymptomatic (silent) AF.The left atrial (LA) anatomy, structure, function and elec-
trophysiology is different than the right atrial (RA). Fibro-
blasts migrate selectively to the LA secreting collagen,
pectin and are not excitable. Fibroblasts produce atrial ﬁbro-
sis and inhomogeneity, which are a good substrate for
arrhythmias.
Recent reports by Marrouche et al., demonstrated that the
magnitude of atrial ﬁbrosis correlates with increased risk of
AF as well as progression from paroxysmal to persistent and
permanent. Furthermore, the presence of increased ﬁbrosis will
lower the success rate of catheter ablation as well as an
increase in the risk of recurrence of AF. Marrouche et al., cat-
egorized the magnitude of atrial ﬁbrosis to Utah 1–4. Utah 1
has 0–5% ﬁbrosis, Utah II >5–20%, Utah III >20–35%
and IV >35% (Ref. 8). Kottkamp recently proposed ﬁbrotic
atrial cardiomyopathy as the substrate for AF.10 Fig. 6 shows
the relationship between magnitude of atrial ﬁbrosis and types
of AF as detected by delayed-enhanced MRI.
3.7. Atrial ﬁbrillation progression
In majority of cases AF may initially present as paroxysmal
form and may progress to persistent and eventually becomeimplantable device in a patient who was recurrent episodes of
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many factors including magnitude of atrial remodeling, associ-
ated structural heart disease and their progression.11 It is
unknown why in some patients it takes a few months for par-
oxysmal AF to become permanent and others 30 years.3.8. Biomarkers of atrial ﬁbrillation (see Table 1)
Certain pathophysiological markers are used to assess the risk
of AF and its progression as well as the response to therapy
and interventions. The most common biomarkers that are used
in clinical practice are B-type natriuretic peptide (BNP) and C-
reactive protein (CRP), which predict the high risk of incident
AF, and its progression. However, most of our biomarkers are
nonspeciﬁc and overlap with other cardiac and non-cardiac
conditions making their clinical utility marginal. It maybe that
in the future the biomarker scores integrated with other risk
score systems to better select high risk individuals, but to date
their clinical appreciation is limited. Other biomarkers like
interleukin-6 and tissue necrosis factors have been reported
and are currently under investigation in large trials.
3.9. Hypertension and atrial ﬁbrillation
Hypertension is the most common risk factor for AF and is
present in 70–80% of patients with AF. Hypertension causes
left ventricular hypertrophy (LVH), diastolic dysfunction, left
atrial hypertrophy and ﬁbrosis, all of which promote AF.
Long-term longitudinal studies from Framingham Heart
Study1 and Women’s Health Study revealed both high systolic
and diastolic BP increase the risk of developing AF.12 Almost
one-third of AF patients with hypertension remain asymptom-
atic. A combination of hypertension and AF is present in 72%
of stroke patients and 82% of patients with chronic kidney dis-
ease, 77% of those with diabetes, 73% of those with CAD,
71% of patients with HF, and 62% with metabolic syndrome.
In addition, hypertension is seen in 49–90% of AF trials.13
LVH alone is an independent risk factor of AF recurrences.
4. Heart failure and atrial ﬁbrillation
4.1. Atrial ﬁbrillation in patients with decreased left ventricular
dysfunction
AF is the most common dysrhythmia in patients with HF and
there exists signiﬁcant association between AF and HF. Both
conditions share many risk factors. AF and HF are two impor-
tant emerging epidemics in medicine.14 AF causes HF and HF
causes AF (HF begets AF and AF begets HF).
The AF–HF cycle: There exists a complex interaction and
relationship between the two diseases. Data from Framingham
study demonstrated that AF and HF often coexist and that
both often have an adverse effect on each other irrespective
of which comes ﬁrst (chicken or the egg). Data from multiple
longitudinal studies suggest AF increases the risk of HF by
2–3 fold, and HF also increases the likelihood of AF and pro-
motes AF from paroxysmal to permanent. About one-third of
patients with HF will develop AF (Fig. 7). The incidence of AF
in patients with HF increases according to the severity of HF
and yet remains diverse. Furthermore, the prevalence of AF inHF increases according to the New York Heart Association
(NYHA) Class ranging from 4% in NYHA Class I to almost
50% in NYHA Class VI. Furthermore, HF poses a signiﬁcant
risk of proarrhythmia in patients treated with antiarrhythmic
agents for AF. A recent trial on the use of dronedarone in
high-risk patients with AF (i.e. those with HF and reduced sys-
tolic function) revealed the unexpected deleterious effect with
increased mortality in patients who received dronedarone com-
pared to a placebo.15
5. Atrial ﬁbrillation in patients with diastolic dysfunction (AF
with preserved LV systolic function)
Diastolic dysfunction is now recognized as an independent risk
factor for incident AF. In patients with diastolic dysfunction,
the most common ﬁndings are left atrial enlargement,
increased left atrial afterload and preload as well as increased
atrial wall stress and ﬁbrosis, as they all promote occurrence of
AF.16 Diastolic dysfunctions share many etiologies with AF
such as hypertension, cardiomyopathies, diabetes.
5.1. Atrial ﬁbrillation and type II diabetes
Type II diabetes is an independent risk factor for developing
AF. Diabetes has been found in 20% of patients with AF
and patients with diabetes have approximately 40% greater
risk of developing AF. The exact mechanism and relationship
between diabetes type II and AF are not fully understood
however it is postulated to be due to atrial patchy amyloid
in the atrium leading to atrial remodeling and ﬁbrosis which
promotes AF.
5.2. Atrial ﬁbrillation and hypertrophic cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is an independent risk
factor for AF and is the most common arrhythmia in patients
with HCM with a prevalence of 22%. As such patients with
HCM carry a 4–6 fold higher risk of developing AF compared
to the general population.17 AF poses an adverse outcome
effect in patients with AF and once AF occurs in patients with
HCM the prognosis is poor. Most patients with HCM have
signiﬁcant hypertrophy, diastolic dysfunction and left atrial
enlargement all of which promote occurrence of AF. Manage-
ment of AF in patients with HCM is a challenge.
5.3. Atrial ﬁbrillation and stroke
AF is found in about 25% of patients admitted with ischemic
stroke and it increases the risk of stroke by 3–6 fold. Stroke is
the most devastating complication of AF and causes death,
neurological deﬁcits, longer hospitalization and disability.
Multiple studies have demonstrated the relationship between
AF and stroke. The Stroke Prevention in Atrial Fibrillation
Study (SPAF III) data showed that up to 45% of the patients
enrolled had ECG documentation of AF.18 Stroke can occur
as the ﬁrst manifestation of AF. A recent study by Healy
et al.,19 demonstrated that the patient with asymptomatic
‘‘silent’’ AF and atrial tachyarrhythmias detected during inter-
rogation of permanent pacemakers and ICDs revealed higher
incidence (50%) of stroke than those without silent AF.
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dia. Another similar study (TRENDS) provided similar data
and conclusions.20 Based on the STROKESTOP trial it is
recommended that patients with silent AF should be screened
for the risk of stroke.21
Several stroke risk prediction scores have been proposed.
The most widely accepted predictor is CHADS2 (Congestive
Heart Failure (CHF), hypertension, age, diabetes, stroke/tran-
sient ischemic attack). Recently CHADS2-VASC score has
been introduced which additionally includes age >65 years,
vascular disease and female sex. CHADS2 has been validated
by several studies and CHADS2-VASC is more popular in
Europe. There is a stepwise approach increase in risk of
stroke as the CHADS2 or CHADS2-VASC score increases
22
(Table 2).
A simpliﬁed approach for real world cases is based on a
patient’s age being over 65 years and presence of any of the
stroke risk factors (CHF, hypertension, diabetes, previous
stroke/transient ischemic attack, vascular disease and female
sex), anticoagulation is recommended. Otherwise no treatment
or aspirin is the recommended management.
5.4. Post-operative atrial ﬁbrillation
AF is the most common arrhythmia after cardiac surgery and
occurs approximately in 20–50% of patients depending on the
type of surgery. AF occurs in 30–40% of patients post
coronary artery bypass graft (CABG) and up to 60–70% of
patients with combined CABG and valve surgery. Almost,
60% of episodes of AF happen in day 2–3 of post op and moreFigure 9 Indications for electrical and pharmacological cardiover
cardioversion in patients with recent-onset AF. Adopted from Camm J
Guidelines for the management of atrial ﬁbrillation. Eur Heart J 2012;3than 50% of patients experience one episode of post-op AF.
The majority of post-op AF converts to sinus rhythm sponta-
neously in the ﬁrst 24–48 h, however if it takes longer than
48 hours it increases the risk of stroke and prolongs hospital-
ization and its related costs. Risk factors and predictors for
post-op AF include older age, male gender, pervious history
of AF, history of previous cardiac surgery, concomitant valve
surgery, LV dysfunction and impaired renal function. In the
postoperative period volume overload, hyper/hypotension,
inﬂammation, post pericardiotomy syndrome are among the
common risk factors for AF.
Post-operative AF affects both early and late mortality
after isolated CABG. Most of the complications are related
to stroke therefore post-operative surveillance and long-term
management with antiarrhythmic agents and antithrombotic
management is warranted.
Preoperative treatments with beta-blockers have been
shown to effectively reduce the risk of AF since inﬂammation
plays a signiﬁcant role in the genesis of post op AF. Colchicine
as well as statins is effective in prevention of this
arrhythmia.23,24.
5.5. Atrial ﬁbrillation in athletes and during endurance exercise
AF is the most common arrhythmia seen in athletes. The inci-
dence of AF in this population depending on the type of sport
ranges from 5 to 10% and is most common in marathon run-
ners, cyclists and cross country skiers. The mechanism(s) of
endurance exercised AF is not fully understood but maybe
related to left atrial enlargement, inﬂammation, remodelingsion, and choice of antiarrhythmic drugs for pharmacological
A, Lip GYH, De Caterina R, et al. 2012 Focused update of the ESC
3:2710–2747.
Figure 10 A and B demonstrates a simpliﬁed approach with antiarrhythmic therapy for rhythm control in patients with normal LV
systolic function (Panel A) and reduced LV systolic function (Panel B).
202 M. Shenasa et al.and ﬁbrosis. As well as left ventricular hypertrophy, enhanced
vagal tone and sinus bradycardia, which is a physiological
response to exercise. Aside from restriction of endurance exer-
cise management of AF in athletes remains the same as others,
however current guidelines recommend to rule out the pres-
ence of associated conditions such as Wolff–Parkinson–White
syndrome, HCM and ARVD/C.25 History, physical examina-
tion, ECG and treadmill test should be part of the workup.265.6. Genetics of atrial ﬁbrillation
Lone AF and those occurring in patients 60 years or younger
have a genetic background and it is important to screen
families with a history of AF in young population. FamilialAF is now a known entity and is often associated with
other inherited channelopathies such as Brugada syndrome,
Long and Short QT syndrome and other sodium-channel
mutations.
The most common type of genetic AF is linked to chromo-
some 4q25.27 In addition, several other genes identiﬁed have
been to be linked to AF such as KCNQ1, KCNE2, SCN5A
and others.
Giustetto et al.28 recently reported on the prevalence of AF
in large patient population with Brugada syndrome. The
results revealed that the prevalence with AF and Flutter is
higher than the general population of the same age. Patients
who developed AF and ﬂutter after the diagnosis of Brugada
ECG are younger, have a greater prevalence of spontaneous
type 1 Brugada ECG and more often experience cardiac arrest.
Figure 11 Illustrates the ESC guidelines for rate control approach in patients with AF. Camm JA, Lip GYH, De Caterina R, et al. 2012
Focused update of the ESC guidelines for the management of atrial ﬁbrillation. Eur Heart J 2012;33:2710–2747.
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those with Brugada Syndrome without AF and Flutter. At
present genetic testing is not recommended.
5.7. Novel risk factors in atrial ﬁbrillation
Several novel risk factors have emerged in relation to AF as
seen in Table 1.
5.8. Atrial ﬁbrillation and obesity
Obesity carries a high risk of developing AF, as it shares multi-
ple etiologies with other comorbidities such as hypertension,
diastolic dysfunction, diabetes type 2, sleep apnea and meta-
bolic syndrome. Obesity adversely affects the response of AF
to antiarrhythmic agents and catheter ablation. Therefore
aggressive lifestyle modiﬁcations should be discussed with the
patient to potentially reduce the risk of AF.295.9. Atrial ﬁbrillation and obstructive sleep apnea
Obstructive sleep apnea (OSA) is a recognized independent
risk factor for AF. In particular nocturnal AF of either parox-
ysmal or persistent type is often detected in patients with OSA.
Thus patients with signiﬁcant OSA should be screened for the
risk of AF and likewise patients with nocturnal AF should be
screened for possible sleep apnea. Appropriate management of
OSA will decrease the incidence of AF. OSA signiﬁcantly
decreases the efﬁcacy of antiarrhythmic agents as well as radio-
frequency ablation of AF.30
6. Atrial ﬁbrillation and kidney disease
Impaired renal function is now recognized among novel risk
factors for incident AF and progression of this arrhythmia.
Chronic kidney disease may be found in about 35% of patients
with AF.31 Patients with end stage renal disease and on kidney
Table 3 Comparison of warfarin to novel oral anticoagulants. Adopted and modiﬁed from Cairn JA. Canadian Journal of
Cardiology 2013;29:1165–1172.
Feature Warfarin Dabigatran Rivaroxaban Apixaban
Mechanism Inhibits synthesis: II, VII, IX, X Direct IIa inhibitor Direct Xa inhibitor Dirext Xa inhibitor
Prodrug No Yes No No
Dose regiment Oral Oral Oral Oral
Administration OD BID OD BID
AF dose (mg) INR 2–3 150, 110, 75 20, 15 5, 25
Food eﬀect Yes Delays absorption Delays absorption No
Food interaction Many No No No
Bioavailability (%) 98 6.5 80–100 50
tmax (h) 72–120 0.5–2 2–4 3–4
T½ (h) 20–60 11–17 5–13 5–13
Substrate CYP 2C9, 3A4 No 3A4, 2J2 3A4
Substrate P-gp No Yes Yes Yes
Renal clearance No 85 33 27
Protein binding (%) 99 35 90–95 87–93
Monitoring INR No No No
AF trial complete Phase III (1989–1992) Phase III (2010) Phase III (2010) Phase III (2011)
Figure 12 Recommendation from ESC Guidelines on AF for the
choice of anticoagulation in AF. (NOAC : novel oral anticoag-
ulant , VKA : vitamin K antagonist) Camm JA, Lip GYH, De
Caterina R, et al. 2012 Focused update of the ESC Guidelines for
the management of atrial ﬁbrillation. Eur Heart J 2012;33:2710–
2747. With permission.
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hand newly diagnosed AF doubles the mortality in patients
with end stage renal disease and those on dialysis. Further-
more, chronic kidney disease is now emerging as an indepen-
dent risk factor for occurrence of AF and stroke.32,33
With increasing use of novel oral anticoagulant (NOAC)
agents, caution should be practiced to the use of these agents
as some of them have signiﬁcant renal clearance such as
Dabigatran.
7. Management of atrial ﬁbrillation
The goals of AF management are:
1. Prevention of recurrences and maintenance of sinus
rhythm.
2. Prevention of AF complications: most importantly stroke
prevention including risk stratiﬁcation for stroke.
3. Prevention of HF.
4. Improving quality of life.
5. Improving survival.
6. Anticoagulation in AF.7.1. Acute management of atrial ﬁbrillation
A majority of patients with acute AF present to hospitals
(emergency rooms). Acute management of AF depends on
the severity of symptoms, which often present as rapid palpita-
tions, increasing shortness of breath, chest pain, light headed-
ness, and rarely syncope. If the patient is hemodynamically
compromised, direct current cardioversion is the safest. If
patients are stable enough pharmacological cardioversion is
done with intravenous Procainamide, Flecainide, Ibutilide,
Vernakalant or Amiodarone depending on the availability of
these drugs34 Fig. 9.
7.2. Drug therapy for atrial ﬁbrillation
Long-term management of AF should be individualized and
evidence based. Selection should be based according to the
Figure 13 A histogram of published articles between 2000 and 2013 in the English language.
Figure 14A Electroanatomical mapping of the left atrium in a posterior–anterior projection illustrates left atrium and pulmonary veins.
Each red dot denotes one ablation lesion for isolation of PVs. CS, coronary sinus; LIPV, left inferior pulmonary vein; LSPV, left superior
pulmonary vein; Posterior LA, Posterior left atrium; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein.
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arrhythmic drugs for AF remain unsatisfactory, antiarrhythmic
therapy remains themainstay ofAFmanagement. Two strategies
of rate control versus rhythm control have been discussed in
length elsewhere. 35 Current evidence suggests that rate control
even lenient rate control is not inferior to rhythm control.7.3. Pharmacologic therapy for rhythm control
In patients with paroxysmal AF with no structural heart dis-
ease and normal LV function, Class I C agents may be used
safely. In patients with congestive HF, Amiodarone is more
effective than Sotalol, but has more non-cardiac side effects.36
Figure 14B Electroanatomical mapping (EMA) and computerized tomography (CT) of the left pulmonary veins. LAA, left atrial
appendage. Abbreviations same as Fig. 14A above.
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fraction37 (Fig. 10).8. Pharmacological therapy for rate control
The selection of pharmacological agents is dictated by a
patient’s type of AF, underlying structural heart disease most
importantly degree and left ventricular dysfunction and coro-
nary artery disease34 Fig. 11.
8.1. Rate versus rhythm control strategies
The rate control strategies became popular after the large
scale AFFIRM Trial: Atrial ﬁbrillation follow up investiga-
tion of rhythm management38–40 was published. The
AFFIRM study included 4060 patients, 65 years and older
with AF and were randomized into rate or rhythm control
strategies. Follow up included stroke, heart failure, hospital-
ization and death. The study found slightly higher trends
toward increased mortality in patients with rhythm control
compared to rate control (p= 0.08). This may have been
due to adverse effect of antiarrhythmic therapy that has off-
set the beneﬁt of sinus rhythm. In a similar trial of rate con-
trol versus electrical cardioversion (RACE Trial), there was
no signiﬁcant difference between rate versus rhythm control
strategy.41
From these controlled randomized trials it can be concluded
that in older and less active individuals who make the majority
cases of AF, a rate control strategy with appropriate stroke risk
stratiﬁcation and anticoagulation therapy is acceptable.
A variety of rate control agents are available including
calcium antagonist, beta-blockers and digoxin. Combinationsof beta-blockers and digoxin have been found to be most
effective.34
In certain young active individuals who remain symptom-
atic rhythm control is preferred over rate control.34
8.2. Arguements in favor of rhythm control approach
Maintenance of sinus rhythm has been associated with improve-
ment in quality of life, left ventricular ejection fraction improved
exercise capacity and left atrial size.42 Furthermore patients who
undergo catheter ablation and maintain sinus rhythm have sig-
niﬁcantly reduced the rate of progression to permanent AF.
8.3. Arguements against rhythm control approach
1. Rhythm control management is often difﬁcult to achieve.
2. Antiarrhythmic drugs have a signiﬁcant side effect includ-
ing proarrhythmic effect.
3. Antiarrhythmic agents are potentially contraindicated in a
large number of patients.
4. Associated structural heart disease and risk factors modu-
late and reduce the response to antiarrhythmic agents and
under certain conditions have a negative effect such as
HF and cardiomyopathies.
5. No evidence that maintaining sinus rhythm will improve
survival.
6. Due to the high incidence of silent AF anticoagulation
needs to be continued.
8.4. Argues in favor of rate control approach
1. Rate control agents are safe and do not produce
proarrhythmia.
bundle and coronary sinus.
Figure 15 (A–C) From our laboratory illustrates a case of AF as detected in intracardiac electrograms from HIS bundle and coronary
sinus electrodes.
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Figure 16 Ablation at the carvo-tricuspid isthmus that abolishes atrial ﬂutter in the same patient as Figs. 14A and 14B. The red dots
denote the site of RF ablation.
Figure 17A ESC guidelines for catheter ablation of AF. Camm
JA, Lip GYH, De Caterina R, et al. 2012 Focused update of the
ESC Guidelines for the management of atrial ﬁbrillation. Eur Heart
J 2012;33:2710–2747. With permission.
Figure 17B 2014 AHA/ACC/HRS Guideline for the Manage-
ment of Patients with AF: Executive Summary. January CT,
Wann S, Alpert JA, et al. J Am College Cardiol 2014.
208 M. Shenasa et al.2. Rate control even lenient rate control approach is not infe-
rior to rate control.3. In patients with CHF large randomized trials have not
shown superiority of rhythm control over rate control in
terms of mortality and hospitalization (Ref. University of
Ottawa pg1156, FALK).8.5. Anticoagulation in atrial ﬁbrillation
In view of the recent experience with NOAC we only summa-
rized the comparison of the three new NOACs with Warfarin.
Oral anticoagulation either with Warfarin or NOACs is rec-
ommended for most patients with AF. Stroke risk scores are
Update on atrial ﬁbrillation 209more useful for small portion of patients in which oral antico-
agulation may not be necessary. Table 3 shows the pertinent
clinical and pharmacological proﬁle of the three NOACs com-
pared to Warfarin.43
The recommendation from ESC Guidelines on AF for
choice of anticoagulants in AF is shown in Fig. 12.
9. Catheter ablation of atrial ﬁbrillation
Since the landmark report of Haissaguerre et al.44 on success-
ful ablation of triggers from pulmonary veins that eliminated
paroxysmal AF was published, a plethora of reports have
emerged (Fig. 13).
9.1. Pulmonary veins and atrial ﬁbrillation
Electrical activity arises from pulmonary veins (PVs) that trig-
gers AF and ablation of these triggers eliminates recurrences of
AF. Many reports have conﬁrmed these observations and PV
isolation (PVI) is now the corner stone of catheter ablation of
AF. Although PV triggers are common they are not exclusive,
as other sources of AF triggers exist.45 Further it has been
demonstrated that left atrial tissue extends 1–3 cm like a
‘‘sleeve’’ into the PVs and carries the same structural and elec-
trical properties.46
The reason then why everyone does not get AF and only
certain individuals develop AF remains elusive of certain
electrical and neurohormonal changes such as stretch,
increased left atrial pressure, may promote trigger activity
in PVs. It is also assumed that there may be an electrical
block between PVs and left atrium under normal conditions.
Once the repeated ﬁring from PVs enters the left atrium
‘‘the substrate’’ initiates AF in a multiple macro-reentrant
circuit either of single or multiple rotors (see mechanism).
Thus elimination of triggers will abolish recurrences of AF
in about 60% of the patients. Failure in the remaining
patients and recurrences is most likely due to incomplete
PVI and presence of the so-called gaps that often necessitate
redo procedures.
9.2. Current status and results of atrial ﬁbrillation ablation
Today catheter ablation of paroxysmal AF is commonly pre-
formed generally after a failure of at least one antiarrhythmicFigure 18 (A) Depicts circular mapping and ablation catheter. (B) Cagent. In 2012 about 50,000 procedures were performed in the
United States. On average the short-term success rate in high
volume experienced centers is about 60% for the ﬁrst proce-
dure and 71% after multiple procedures. 15–35% of patients
undergo a redo procedure.47
PVI remains the cornerstone of AF ablation, which is often
effective in 50–60% of patients with paroxysmal AF
(Figs. 14A and 14B).
Substrate modiﬁcation, i.e., left atrial and other sources are
often necessary in cases of persistent and long-lasting persis-
tent AF. In more complex cases extensive substrate modiﬁca-
tion including rooﬂine, posterior left atrial wall ablation;
ablation around the left atrial appendage may be needed.
Fig. 15A–C is from our laboratory illustrates a case of AF
as detected in intracardiac electrograms from His bundle and
coronary sinus electrodes. Occasionally after termination of
AF, atrial ﬂutter emerges may necessitate ablation at the
carvo-tricuspid isthmus as shown in Fig. 16. Extensive abla-
tion to the left atrium in some cases produces left atrial tachy-
cardia/ﬂutter at the mitral isthmus that also may require
ablation of that region.
Several randomized trials have compared catheter ablation
with antiarrhythmic agents in a randomized fashion. All the
reported trials were designed to include symptomatic patients
with paroxysmal, persistent and long lasting persistent AF
who have failed at least one antiarrhythmic agent. All these tri-
als have shown superiority of catheter ablation over antiar-
rhythmic therapy in terms of symptom relief, recurrences,
quality of life and outcome issues.
Experimental and clinical reports suggest that neural pelxi
that lie over the junction of PVs and left atrium may serve
as a source of inducing and maintain AF. High frequency stim-
ulation of neural plexi in both animals and humans demon-
strated to induce AF and thus attempts to ablate neural
plexi have resulted in the elimination of AF. To date there
are no randomized trials comparing PVI with neural plexi
ablation in patients with AF.48
Thus, catheter ablation of AF in patients with paroxysmal
type with no to minimal structural heart disease may now be
considered as ﬁrst line therapy and is considered reasonable
in patients with paroxysmal and persistent AF.33 Fig. 17A
shows the ESC guidelines and Fig. 17B illustrates the Ameri-
can College of Cardiology, American Heart Association and
Heart Rhythm Society 2014.ryoballoon ablation catheter. Image courtesy of Medtronic, Inc.
Figure 19 CT angio and Fly Thru of the LA and Pulmonary Veins. (LA : left Atrium).
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Based on the Meta-analysis results, 9 studies with 27,402
patients, undergoing uninterrupted anticoagulation therapy
with Warfarin have signiﬁcantly reduced the risk of thrombo-
embolic complication without an increased risk of bleeding.49
9.4. Strategies for catheter ablation of atrial ﬁbrillation
Different approaches for catheter ablation of AF have been
used in different centers as summarized below.
1) Anatomical approach: PV isolation, roof-lines, box
lines.
2) Substrate based approach. Electrogram based.
 Electrogram fractionation (Complex Fractionated
Atrial Electrograms (CFAE)).50
 Neural Plexi.483) Etiology and mechanism based approach.
The Bordeaux group ﬁrst reported on a stepwise approach that
is currently adopted in many centers. In this approach the proce-
dure begins with PVI and according to the termination or extent
of underlying atrial remodeling a roof line followed by mitral isth-
mus line, followed by anterior mitral isthmus line and inferior and
posterior lateral lines that completes the left atrial box.51–53
9.5. Rotor ablation in patients with AF
Evidence from patients with AF and from experimental studies
has suggested that single or multiple rotors maybe operated in
AF and elimination of rotors have terminated the AF in these
models. Recently, Narayan et al.54 have demonstrated single
rotors in human AF and ablation of these rotors have elimi-
nated AF without additional ablation of the PV and other
sites. A randomized trial is currently under investigation.9.6. Techniques for atrial ﬁbrillation ablation
1. Radiofrequency ablation.
According to the initial report of Haissaguerre et al.,44 the
triggers were within the PVs and radiofrequency (RF) currents
were delivered within the PVs have eliminated AF. However,
follow up reports showed PV stenosis have developed with
signiﬁcant symptoms that in some patient interventions were
needed to correct it by stenting. Currently, PVI around the
antrum is a common practice.
10. Cryoballoon ablation
This balloon based ablation system freezes the antrum of the
PVs. The cryoballoon ablation isolates PVs by freezing them
at 80. A few randomized trials have compared RF ablation
with cryoballoon ablation techniques as seen in Fig. 18A and B.
11. Results of catheter ablation
The best results of PVI are obtained in patients with parox-
ysmal AF with no structural heart disease. The acute success
rate is about 57% (50–60%). The success rate of multiple
procedures without antiarrhythmic agents is at best 71%
(65–77%) and multiple procedures with antiarrhythmic
agents are 77% (73–81%).47 The immediate 3 months are
considered a blanking period as many asymptomatic recur-
rences have been detected. Weerasooriya et al.55 reported
on the long-term results after multiple catheter ablation pro-
cedures of AF having shown that the sinus rhythm main-
tained at 1, 2, and 5 years was 87%, 81% and 63%.
However after a single procedure 40%, 37% and 29% at
1, 2 and 5 years were reported.55 The associated comorbidi-
ties such as hypertension, diastolic dysfunction, heart failure,
obstructive sleep apnea, obesity and impaired renal function
have shown to lower the success rate of catheter ablation of
AF and increase recurrences.
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Catheter ablation of AF is taken with much enthusiasm and the
ablationists promoting that the long term outcomes of AF abla-
tion are superior to antiarrhythmic therapy. However, there are
no large randomized trials to show that the catheter ablation is
superior to medical management in terms of reduction of mor-
tality, stroke, hospitalization, and improvement in heart failure.
Only the MANTRA trial demonstrates that after 2 years the
quality of life was better compared to antiarrhythmic therapy.
A very recent trial comparing antiarrhythmic therapy to radio-
frequency ablation of AF as ﬁrst line therapy just published
showed a lower rate of recurrent paroxysmal AF in patients
who underwent catheter ablation of AF.56,57. It is hoped that
with early intervention and maintenance of sinus rhythm, atrial
remodeling is minimized and improves the burden of AF. At
present no data has demonstrated that maintaining sinus
rhythm with catheter ablation will reduce the death rate related
to AF. Recently Mont et al.58 reported on catheter ablation vs.
antiarrhythmic drug treatment of persistent AF: a multicenter,
randomized, controlled trial (SARA study). The results revealed
that catheter ablation was superior to medical therapy in main-
taining sinus rhythm in patients with persistent AF during a 12-
month follow up. The shortcoming of this trial was that the trial
was terminated prematurely due to low patient recruitment and
the primary endpoint of the study was only recurrences of AF
24 h after ablation.
Dagres et al.,59 reported on a meta-analysis of randomized
trial that there were no mortality beneﬁts of catheter ablation
over drug therapy. Similarly two Canadian trials of AF-CHF60
and the RAAFT study (ﬁrst line radiofrequency ablation ver-
sus antiarrhythmic drugs for atrial ﬁbrillation treatment) did
not show mortality beneﬁt of catheter ablation.12. Imaging before and during AF ablation
(1) Preprocedure imaging includes transthoracic echocar-
diogram, cardiac computerized tomography (CT) to
evaluate left atria and PVs geometry and its branch as
seen in Fig. 19.
(2) Intraprocedural imaging includes magnetic resonance
imaging (MRI) to evaluate the degree of ﬁbrosis, intra-
cardiac echocardiography (ICE), electroanatomical
mapping, magnetic resonance imaging and direct visual-
ization of ablation lesion (currently under investigation).
13. Complication of catheter ablation
Catheter ablation of AF is now an established procedure and
has a low incidence of procedural complications in experienced
and high volume centers. Two worldwide surveys by Cappato
et al. have reported on the safety and complication of catheter
ablation of AF, initially in 200561 and again in 2010.62 Gupta
et al.63 recently reported a systemic review of 192 studies with a
total of 83,236 patients with periprocedural complication rate
of 2.6–3.2% in catheter ablation of AF.
The most common acute complications include vascular
complications including atriovenous ﬁstula, femoral pseudoan-
eurysm, stroke and TIA. PV stenosis (less often seen as PV iso-lation is preformed at the antrum of PVs), tamponade,
pericardial effusion, phrenic nerve injury, pneumothorax/hemo-
thorax, sepsis and valve damage.However, themost devastating
complications are death, stroke and atrioespohageual ﬁstula.
The predictors of complications are related to the operators
experience, low volume centers and extent of other
comorbidities.63
Two recent reports on complications of catheter ablation of
AF have been published.64,65 The most common complication
of cryoballoon procedure is phrenic nerve palsy, which often
resolves spontaneously however occasionally permanent dam-
age may occur. Lee et al. recently reported a low risk of major
complications in 500 consecutive patients who underwent PVI
only for paroxysmal AF.66 Therefore overall catheter ablation
of AF appears to be safe and effective in a selected patient
population.
14. Ablate and PACE
In patients who are not appropriate candidates of AF ablation
and adequate rate control with pharmacological agents cannot
be achieved, AV-nodal ablation and pacemaker implantation
maybe considered. In this group those with heart failure may
beneﬁt from biventricular devices.67–69
14.1. Left atrial appendage (LAA) closure for stroke prevention
In patients who are not a candidates for antithrombotic
agents and are at risk for stroke, left atrial appendage
(LAA) closure either surgically or with implantation of
devices appears reasonable. Currently, several devices are
under investigation and the most commonly used is the
Watchman device.70 The PROTECT-AF trial was designed
to prospectively evaluate the safety and efﬁcacy of the
Watchman device in 59 centers. A total of 707 patients with
CHADS2 score of >1 were enrolled and in 89.5% of
patients successful implantation was achieved. The trial con-
cluded that the LAA closure was not inferior to systemic
anticoagulation to Warfarin.71 Other devices such as the
Lariat (SentreHeart, Inc.) is a percutaneous suture ligation
for LAA closure is also under investigation.70,72
14.2. Uncertainties in catheter ablation of AF
When catheter ablation was initially introduced for more dis-
crete cases such accessory pathways and AV nodal reentrant
tachycardias.
There existed a large experience in electrophysiology
studies deﬁning the characteristics of tachycardia circuits as
well as experience obtained from surgical cases. Thus it
was the best of times; and it was the age of wisdom. How-
ever in AF ablation, it was the worst of the times; it was the
age of foolishness.73 Thus in the former scenario, the proce-
dure was more successful (90%) with a very low complica-
tion rate. However in case of AF after the Haisseguerre
and colleagues landmark report ‘‘Spontaneous initiation of
atrial ﬁbrillation by ectopic beats originating in the pulmon-
ary veins,’’ many centers have begun to perform the proce-
dure without scientiﬁc background in a more complex and
heterogeneous substrate.7
Figure 20 Opportunities and challenges for future AF. AF, atrial ﬁbrillation; AA, antiarrhythmic therapy; SHD, structural heart
disease; HF, heart failure; CRT, cardiac resynchronization therapy; NOAC, novel oral anticoagulants; LAA, left atrial appendage; CHF,
chronic heart failure; NOAC, novel oral anticoagulants; Echo, echocardiography; CT, computerized tomography; MRI, magnetic
resonance imaging.
Figure 21 Final common pathways of diverse etiologies of inﬂammation, ﬁbrosis and remodeling lead to AF.
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Update on atrial ﬁbrillation 21314.3. Should catheter ablation be the ﬁrst line therapy for
patients with AF?
Controversies continue surrounding whether catheter ablation
should be offered as ﬁrst line therapy in patients with paroxys-
mal AF. Few studies have prospectively and in a randomized
fashion have assessed the outcome of catheter ablation of
AF as the ﬁrst line therapy. The available data indicate that
the efﬁcacy of catheter ablation as a ﬁrst line therapy is at least
equivalent74 or better56 than the ﬁrst line antiarrhythmic drug
therapy. Quality of life appears to be better in the ablation
group compared with antiarrhythmic therapy. Thus current
evidence supports the position of European Society of Cardi-
ology, AF guidelines, as ﬁrst line therapy in symptomatic par-
oxysmal AF appears reasonable in experienced centers.
14.4. Deﬁnition of successful procedure
The Heart Rhythm Society consensus on AF published in 2012
deﬁned success as freedom from any symptomatic or asymp-
tomatic AF of any type, atrial tachycardia or ﬂutter longer
than 30 s, 12 months after the procedures. However for practi-
cal purpose a signiﬁcant reduction in AF burden as well as sig-
niﬁcant reduction in symptomatic AF is considered a clinical
success. The limitation of these deﬁnitions is however the
uncertainty of duration of monitoring post ablation.
14.5. Duration of post ablation monitoring
It has been recognized that during the ﬁrst 3 months post AF
ablation there are signiﬁcant short and long term AF
recurrences. Therefore this period is arbitrarily designed as
‘‘blanking period’’ which may be due to the signiﬁcant amount
of tissue damage and edema that promotes AF.
14.6. Procedural end points
At present there is no uniform agreement on what is accepted as
end points of catheter ablation. These uncertainties are due in
part to the following issues: (1) AF types, i.e., paroxysmal, per-
sistent and long lasting persistent. (2) Ablation protocols, i.e.,
PVI only or additional ablation. (3) Ablation techniques i.e.
radiofrequency, cyroablation, laser, etc. (4) Immediate post
ablation protocol, i.e., burst pacing, isoproterenol infusion,
adenosine–triphosphate administration etc. (5) Duration and
methods of rhythm monitoring.
14.7. Cost of catheter ablation of atrial ﬁbrillation
Catheter ablation is an expensive procedure with the initial
cost and 5 year follow up totaling a sum of $30,000–35,000
per patient in the United States.55,79 McKenna et al.76 report
the cost of catheter ablation in United Kingdom to be
7700 - 7900 pound while Canada having a cost of $16,278.75–7715. Future directions in catheter ablation of atrial ﬁbrillation
Due to relatively high recurrence rates even after the blanking
period and the need for repeatedprocedure, newer ablation tech-
nologies are sought. Endoscopic navigation and visualization ofthe target tissue and ablation effect on the atria are under inves-
tigation. Preliminary reports have examined the feasibility of
this method in experimental animal and the ﬁrst 200 patients.78
(1) Recent reports revealed that case done in community
hospitals with low volume procedures had higher com-
plication rates of about 6.2%. Whereas procedures
that are performed in high volume centers with expe-
rienced operators had lower complication rates
(3.9%).61–64
(2) Direct vision during catheter ablation to better identify
the target tissue and its effect on the atrial tissue.78,79
(3) Since radiation during the procedure is an important
issue to the patient, operator and cath lab staff,
newer technologies are emerging to use ionized radia-
tion free techniques such as magnetic resonance
guided EP study and ablation. Preliminary results
are favorable however; no long-term results are
available.
15.1. Concepts to consider in the future management of AF
 Selective ion channel blockers.
 Multi-channel blockade (like Amiodarone, Dronedarone
and Ranolazine).
 Atrial channel selective (usually ‘‘relative’’).
 Substrate based mapping and ablation.
– Gap junction conduction.
– Fibrosis.
– Inﬂammation.
Future AF management should focus on personalized risk
factors that better predict the best approach (pharmacological
or nonpharmacological), identify risk and biomarkers as well
as better understanding of genetic, environmental interaction
with such complex arrhythmias. At the same time improve-
ment in AF detection tools and imaging techniques of both
the heart and brain to better understand the pathophysiology
of AF, i.e., ‘‘system biology.’’ Furthermore, the burden of
ﬁbrosis should be on the future agenda.
16. Future opportunities
(1) Noninvasive characterization of AF and its types maybe
useful in the identiﬁcation of patient proﬁles.
(2) At present there are no uniform protocols for cathe-
ter ablation of AF and it remains empirical. Hope-
fully the future trials will provide insights to design
uniform protocols. This inconsistency maybe imparted
due to the complexity of substrate and presence of
evolving underlying heart disease such as HF, hyper-
tension. As such there remain many unanswered
questions like endpoints, follow-ups and deﬁnition
of success, etc.
(3) Atrial selective antiarrhythmic and upstream therapy
will continue to expand.
(4) Results and technology of catheter ablation of AF will
expand.
(5) The design of future trials should attempt to answer
some of the following questions::
1. What is the best method and duration of rhythm
monitoring post ablation?
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approaches in paroxysmal and persistent AF, i.e.,
PVI only versus PVI and substrate modiﬁcation
and neuraplexi ablation, rotor ablation, etc.
3. Can anticoagulation be discontinued in some
patients if they maintain sinus rhythm?
4. Best outcome measures, AF recurrences, hospital-
ization, stroke, death and quality of life.
5. Cost-effectiveness of catheter ablation.16.1. Future trials
(1) Catheter ablation vs. anti-arrhythmic drug therapy for
atrial ﬁbrillation trial (CABANA).80
(2) Early treatment of atrial ﬁbrillation for stroke preven-
tion trial (EAST).81
(3) Rate vs. catheter ablation rhythm control in patients
with heart failure and high-burden atrial ﬁbrillation
(RAFT-AF).82,83
(4) First line radiofrequency ablation vs. antiarrhythmic
drugs for atrial ﬁbrillation treatment (The RAAFT
Study).84
(5) Delayed-Enhancement MRI Determinant of Successful
Radiofrequency Catheter Ablation of Atrial Fibrillation
(DECAAF)8517. Summary
In summary AF prevalence and incidence are increasing by age.
Aggressive risk stratiﬁcation and preventive measures should be
part of management. The management should focus on four
strategies: (1) Prevention of arrhythmia and progression from
paroxysmal to persistent and permanent forms, (2) stroke
risk assessment and prevention of embolic complications, (3)
arrhythmiamanagement according to the guidelines and patient
underlying structural heart disease, and (4) treatment of the
underlying causes.
Our current biomarkers for AF are nonspeciﬁc, however
a multimarker approach may improve their sensitivity.
Improved detection methods of AF especially after antiar-
rhythmic therapy and ablative procedures are important.
Overall, trials to date have failed to show that rhythm con-
trol approach is superior to rate control approach in all-
composite measures, although some trials have shown that
patients who maintained sinus rhythm reported improved
quality of life.
According to the recent evidence based and guidelines cath-
eter ablation of AF seems reasonable in patients with paroxys-
mal AF with no to minimal structural heart disease who have
failed at least one antiarrhythmic agent. Aggressive risk mod-
iﬁcation of comorbidities such as obesity sleep apnea, impaired
renal function. is necessary and should be an integral part of
AF management. Finally, Berti et al. proposed a multidisci-
plinary nurse-coordinated AF program to improve detection
management and outcome of patients with AF. This approach
will begin with comprehensive risk assessment, patient educa-
tion, patient centered medical care and evaluation of manage-
ment outcome.86
As AF is an evolving disease we will witness a signiﬁcant
paradigm shift in understanding the pathophysiology andmanagement of AF. Fig. 20 demonstrates the opportunities
and challenges for future AF.
Finally, all AF patients are not the same and AF is not a
disease it is a symptom like fever, syncope, etc. Management
should be etiology based rather than mechanism based. Pre-
vention should be the ﬁrst line of therapy. As inﬂammation,
ﬁbrosis and remodeling are the ﬁnal common pathway of
diverse etiologies, innovative therapies should focus on ﬁbrosis
and inﬂammation as shown in Fig. 21.Conﬂict of Interest
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